Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.
Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension
- Conditions
- Hypertension Resistant to Conventional Therapy
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Sao Jose do Rio Preto Medical School
- Target Recruit Count
- 72
- Registration Number
- NCT02832973
- Locations
- 🇧🇷
Juan Carlos Yugar-Toledo, São José do Rio Preto, São Paulo, Brazil
High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2019-05-03
- Target Recruit Count
- 48
- Registration Number
- NCT02823626
- Locations
- 🇺🇸
Shweta Bansal, San Antonio, Texas, United States
Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Svendborg Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT02764619
- Locations
- 🇩🇰
Department of Cardiovascular Research, Medical Department, Odense University Hospital, Svendborg, Svendborg, Region of Southern Denmark, Denmark
Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT02689843
- Locations
- 🇮🇷
Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of
Spironolactone in Atrial Fibrillation
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 250
- Registration Number
- NCT02673463
- Locations
- 🇬🇧
University of Birmingham Institute of Cardiovascular Sciences, Birmingham, West Midlands, United Kingdom
Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 20
- Registration Number
- NCT02585843
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
- Conditions
- AML
- Interventions
- Biological: Lintuzumab-Ac225
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Actinium Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02575963
- Locations
- 🇺🇸
University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Columbia University Medical, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸St. Francis Cancer Center, Greenville, South Carolina, United States
Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Target Recruit Count
- 24
- Registration Number
- NCT02531412
- Locations
- 🇲🇽
Nacional Cancer Institute, Mexico, Distrito Federal, Mexico
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD
- Conditions
- Renal Insufficiency, ChronicCardio-Renal Syndrome
- Interventions
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- University Hospital Birmingham
- Target Recruit Count
- 154
- Registration Number
- NCT02502981
- Locations
- 🇬🇧
Royal Free Hospital, London, United Kingdom
🇬🇧Departments of Cardiology & Nephrology University Hospital Birmingham, Birmingham, West Midlands, United Kingdom
🇬🇧University of Edinburgh: BHF Centre for Cardiovascular Science and Western General Hospital, Edinburgh, United Kingdom
Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 14
- Registration Number
- NCT02501213
- Locations
- 🇫🇷
Centre Hospitalier Intercommunal Compiègne-Noyon, Compiègne, France
🇫🇷Polyclinique de Grande Synthe, Grande Synthe, France
🇫🇷CHRU Lille, Lille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.